[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"viral-hepatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:viral-hepatitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100357388","phase-4-tenofovir-alafenamide-versus-entecavir-for-the-treatment-of-chronic-hepatitis-b-100357388",false,"NCT03933384","Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B","Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients more than 20 years old\n2. Chronic hepatitis B patients\n3. Patients who were indicated for hepatitis B virus antiviral therapy\n\nExclusion Criteria:\n\n1. Decompensated liver disease (Child-Pugh B \\&C)\n2. End stage renal disease (eGRF \\\u003C 15 ml\u002Fmin\u002F1.73m2)\n3. Prior use of nucleot(s)ide analogues for chronic hepatitis B\n4. Prior use of interferon for chronic hepatitis B within six months\n5. Known history of human immunodeficiency virus or hepatitis C virus co-infection\n6. Concurrent other uncontrolled malignancy\n7. Women in pregnancy or lactation\n8. Cannot conform to the study protocol of this study","ALL","20 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.",[26,27],"Hepatitis B","Viral Hepatitis",[26,27,29,30],"Tenofovir alafenamide","Entecavir","RECRUITING","2026-05-11",{"date":34,"type":35},"2026-05-14","ACTUAL",{"date":37,"type":35},"2019-08-19",{"date":39,"type":20},"2030-12-31",{"name":41,"class":42},"Taichung Veterans General Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100585627","acceptability-and-feasibility-of-simultaneous-screening-for-viral-hepatitis-b-c-and-hiv-among-drug-users-and-vulnerable-populations-in-non-conventional-structures-outside-the-walls-by-dual-screening-method-rtds-and-fibroscan-100585627","NCT06904820","Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures \"Outside the Walls\" by Dual Screening Method RTDs and FibroScan®","SCANVIRE2","Inclusion Criteria:\n\n* Adult 18 and over\n* Patient frequenting an unconventional structure \"outside the walls\" or referred by a professional in the care sector\n* Patient not opposed to research\n\nExclusion Criteria:\n\n* Age under 18\n* Patient opposed to research","18 Years",{"count":53,"type":20},2300,"1 Day","OBSERVATIONAL","The \"Scanvir\" concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient's health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a \"test, treat and cure\" strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers.",[27],[59,60,61],"HCV","eradication","marginalized patients","2025-08-13",{"date":64,"type":35},"2025-08-14",{"date":66,"type":35},"2025-06-05",{"date":68,"type":20},"2035-06-05",{"name":70,"class":42},"University Hospital, Limoges"]